SCHEMBL30749060

SCHEMBL30749060

C[C@@H]1C[C@H](C)CN(c2ncc(B(O)O)cc2F)C1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 1/20 0.35
NPC1 O15118 2/20 0.33
ALDH1A1 P00352 2/20 0.33
RAB9A P51151 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 2/20 0.33
HTT P42858 1/20 0.33
HPGD P15428 1/20 0.33
PDE1B Q01064 1/20 0.32
CNR2 P34972 1/20 0.32
ACACB O00763 4/20 0.32
LMNA P02545 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
HSD17B10 Q99714 1/20 0.32
LRRK2 Q5S007 1/20 0.32
KDM4E B2RXH2 2/20 0.31
CYP1A2 P05177 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30748905 0.78 ACACB (0.45) MAP2K7NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL31458782 0.74 JAK1 (0.43)
SCHEMBL31458783 0.74 JAK1 (0.43)
SCHEMBL20071202 0.74 JAK1 (0.43)
SCHEMBL1708597 0.74 KDM4E (0.48) NPC1RAB9ASMN1; SMN2CNR2LMNA
SCHEMBL29455297 0.71 NPC1 (0.41) MAP2K7NPC1ALDH1A1RAB9ASMN1; SMN2
SCHEMBL20354142 0.71 ACACB (0.46) ACACB
SCHEMBL27099112 0.70 OPRK1 (0.35) ACACB
SCHEMBL25930955 0.69 KDM4E (0.38) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL15414567 0.69 BACE1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2025-10-02 US disclosed
EP-4565588-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF Suzhou Keen Therapeutics Co., Ltd. (CN) 2025-06-11 EP disclosed
WO-2023241620-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) 2023-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250304571-A1 BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF VHL, BRCA1, TERT MAP2K7 4634/4885NPC1 1432/4885ALDH1A1 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.